Could a common drug boost brain power in kids with rare syndrome?
NCT ID NCT01619644
First seen May 16, 2026 · Last updated May 20, 2026 · Updated 2 times
Summary
This study tested a medicine called sodium valproate in children aged 6 to 21 with Rubinstein-Taybi syndrome, a genetic condition that affects learning and movement. For one year, some children received the drug and others received a placebo. The goal was to see if the drug could improve memory and fine motor skills, using tests, brain scans, and blood work. The study is complete and involved 41 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RUBINSTEIN-TAYBI SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Bordeaux, France
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.